正海生物(300653) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥109,080,515.27, representing a decrease of 7.35% compared to ¥117,732,128.60 in the same period last year[5] - Net profit attributable to shareholders was ¥53,398,823.33, down 2.95% from ¥55,019,970.53 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 109,080,515.27, a decrease from CNY 117,732,128.60 in the previous period[19] - Net profit for Q1 2023 was CNY 53,398,823.33, compared to CNY 55,019,970.53 in the same period last year, reflecting a decline of approximately 2.9%[20] - Earnings per share (EPS) for Q1 2023 was CNY 0.30, slightly lower than CNY 0.31 in the previous year[20] Cash Flow and Liquidity - Operating cash flow net amount decreased by 20.45% to ¥51,412,656.21 from ¥64,628,035.53 in the previous year[5] - The net cash flow from operating activities was ¥51,412,656.21, a decrease of 20.4% compared to ¥64,628,035.53 in the previous period[22] - Cash inflow from operating activities totaled ¥115,002,511.65, down from ¥123,118,084.20, reflecting a decline of 6.4%[22] - Cash outflow from operating activities increased to ¥63,589,855.44 from ¥58,490,048.67, representing an increase of 8.5%[22] - The net cash flow from investment activities was ¥83,072,126.87, a significant improvement from -¥16,860,975.69 in the previous period[22] - The net increase in cash and cash equivalents was ¥134,484,783.08, compared to ¥47,767,059.84 in the previous period, indicating a substantial increase[23] - The ending balance of cash and cash equivalents was ¥191,530,405.87, up from ¥160,415,416.11, reflecting a growth of 19.4%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,019,909,889.77, reflecting a 3.34% increase from ¥986,904,775.50 at the end of the previous year[5] - Total liabilities decreased to CNY 101,403,274.79 from CNY 121,796,983.85, indicating a reduction of about 16.8%[18] - The total equity attributable to shareholders increased to CNY 918,506,614.98 from CNY 865,107,791.65, marking an increase of approximately 6.2%[18] - The total current assets amount to ¥747,503,222.35, up from ¥710,006,315.27, indicating an increase of 5.2%[16] - The total fixed assets increased to ¥223,077,762.64 from ¥213,402,856.90, reflecting a growth of 4.0%[16] Research and Development - Research and development expenses increased by 56.26% to ¥11,822,835.70, driven by more clinical stage projects[8] - Research and development expenses rose significantly to CNY 11,822,835.70 from CNY 7,565,929.03, reflecting an increase of about 56.5%[19] - The company has entered clinical trials for its product, the intrauterine repair membrane, as of February 21, 2023[13] - The company received acceptance for its medical device registration application for phosphoric acid etching agent on March 21, 2023[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13.615 million[11] - The largest shareholder, Mipo Hai, holds 33.87% of shares, totaling 60,961,500 shares, with 16 million shares pledged[11] - The company has a total of 10 major shareholders with varying ownership percentages, the largest being 33.87%[11] Other Financial Metrics - The weighted average return on equity decreased to 5.99% from 6.77% in the previous year[5] - The company reported a significant decrease of 88.52% in other operating income, amounting to ¥1,540.02 compared to ¥13,412.00 in the previous year[9] - Investment income for the period was ¥6,914,978.50, a notable increase from zero in the same period last year[8] - The company experienced a 162.11% increase in credit impairment losses, totaling -¥79,228.07, due to higher bad debt provisions[8] - The company reported a financial income of CNY 337,646.29, up from CNY 239,121.92 in the previous period[19] - The deferred income tax assets decreased slightly to CNY 2,646,980.29 from CNY 2,668,398.16[17] - The company reported a cash outflow of ¥3,441,000.76 for purchasing goods and services, down from ¥8,199,637.22, a decrease of 58.1%[22] - The company paid ¥23,647,235.15 in employee compensation, a decrease from ¥25,934,195.12, indicating a reduction of 8.8%[22] - The company did not report any cash inflow from financing activities during the period[22]